Hannah Gilman
YOU?
Author Swipe
View article: Exploring and Explaining the Use and Proliferation of Whole Life Orders in England and Wales
Exploring and Explaining the Use and Proliferation of Whole Life Orders in England and Wales Open
Whole life orders (WLOs) represent the power of the state to inflict harm at its most extreme, with such sentences being found to be in breach of the European Convention on Human Rights. However, very little research has endeavoured to und…
View article: Atorvastatin and left atrial function during anthracycline-based chemotherapy
Atorvastatin and left atrial function during anthracycline-based chemotherapy Open
NCT02943590; https://clinicaltrials.gov/study/NCT02943590.
View article: Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP Open
STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We performed a preplanned subgroup to analyze …
View article: Atrial and ventricular arrhythmias with immune checkpoint inhibitor therapy in patients without evidence of myocarditis
Atrial and ventricular arrhythmias with immune checkpoint inhibitor therapy in patients without evidence of myocarditis Open
Background Immune checkpoint inhibitor (ICI) therapy has improved the prognosis of many cancer types. Immune-related adverse events (irAEs) are common and recent studies suggest ICI therapy may be associated with an increased risk of arrhy…
View article: Atorvastatin for Anthracycline-Associated Cardiac Dysfunction
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction Open
Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with a reduction in cardiac dysfunction due to anthracycline use. Objective To test w…
View article: Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer Open
Background Patients with lung cancer face a heightened risk of atherosclerosis-related cardiovascular events. Despite the strong scientific rationale, there is currently a lack of clinical evidence examining the impact of immune checkpoint…
View article: Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy
Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy Open
View article: Association between immune checkpoint inhibitors and vascular endothelial growth factor targeted therapy with cardiovascular events
Association between immune checkpoint inhibitors and vascular endothelial growth factor targeted therapy with cardiovascular events Open
Background The use of immune checkpoint inhibitors (ICI) has been associated with a 3-fold higher risk for cardiovascular events as compared to cancer patients who did not receive ICI. Therapies targeting vascular endothelial growth factor…
View article: Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis
Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis Open
View article: The Prediction of Cardiac Events Using Contemporary Risk Prediction Models after Radiation Therapy for Head and Neck Cancer
The Prediction of Cardiac Events Using Contemporary Risk Prediction Models after Radiation Therapy for Head and Neck Cancer Open
This study aims to evaluate the efficacy of the Pooled Cohort Equation (PCE), U.S. Preventative Services Task Force (USPSTF), and Framingham Risk Score (FRS) models in predicting ASCVD events among patients receiving radiation therapy (RT)…
View article: Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines Open
View article: The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm Open
Background Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy. Beyond switching to non-5FU-based chemotherapy, there are no established treatments for 5-FU associated coronary vasospam. Our objective was to assess the…
View article: Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors
Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors Open
In this large retrospective study, patients with hypertension who were concomitantly taking a RAAS inhibitor during ICI therapy had better overall survival. This benefit was primarily noted among patients with gastrointestinal and genitour…
View article: Immune checkpoint inhibitors for cancer and venous thromboembolic events
Immune checkpoint inhibitors for cancer and venous thromboembolic events Open
View article: Pericardial disease in patients treated with immune checkpoint inhibitors
Pericardial disease in patients treated with immune checkpoint inhibitors Open
Background There are limited data on the occurrence, associations and outcomes of pericardial effusions and pericarditis after treatment with immune checkpoint inhibitors (ICIs). Purpose To evaluate incidence of pericardial disease in pati…
View article: Pericardial disease in patients treated with immune checkpoint inhibitors
Pericardial disease in patients treated with immune checkpoint inhibitors Open
Background There are limited data on the occurrence, associations and outcomes of pericardial effusions and pericarditis on or after treatment with immune checkpoint inhibitors (ICIs). Methods This was a retrospective study at a single aca…
View article: EFFECT OF TOCILIZUMAB ON CARDIAC INJURY AND DYSFUNCTION IN COVID-19
EFFECT OF TOCILIZUMAB ON CARDIAC INJURY AND DYSFUNCTION IN COVID-19 Open
View article: MYOCARDIAL T1 AND T2 MAPPING BY CARDIOVASCULAR MAGNETIC RESONANCE IN IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MYOCARDITIS
MYOCARDIAL T1 AND T2 MAPPING BY CARDIOVASCULAR MAGNETIC RESONANCE IN IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MYOCARDITIS Open
View article: Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
Electrocardiographic features of immune checkpoint inhibitor associated myocarditis Open
Background Myocarditis is a highly morbid complication of immune checkpoint inhibitor (ICI) use that remains inadequately characterized. The QRS duration and the QTc interval are standardized electrocardiographic measures that are prolonge…
View article: Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis Open
View article: The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm Open
View article: Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors Open
Summary Objectives Skeletal myopathies are highly morbid, and in rare cases even fatal, immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI). Skeletal myopathies are also a recognized statin-associated si…
View article: Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis
Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis Open
Background Myocarditis attributable to immune checkpoint inhibitor (ICI) therapy is a potentially fatal immune‐related adverse event. Limited data have suggested an association between baseline and on‐treatment absolute lymphocyte count (A…
View article: Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque Open
Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers. Consistent basic data suggest that these same checkpoints are critical negative regulators of atherosclerosis. Therefore, our objectives were to test whet…
View article: A Brief Exploration of Sexual Education
A Brief Exploration of Sexual Education Open